Ticker Details
Blueprint Medicines Corporation Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
IPO Date:	May 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.35B
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$1.46 | 2.35%
Avg Daily Range (30 D):	$0.10 | 0.07%
Avg Daily Range (90 D):	$1.18 | 1.27%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	1.55M
Avg Daily Volume (90 D):	2.37M

Trade Size
Avg Trade Size (Sh.):	69
Avg Trade Size (Sh.) (30 D):	204
Avg Trade Size (Sh.) (90 D):	123

Institutional Trades
Total Institutional Trades:	6,903
Avg Institutional Trade:	$3.91M
Avg Institutional Trade (30 D):	$13.73M
Avg Institutional Trade (90 D):	$8.69M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.49M
Avg Closing Trade (30 D):	$163.6M
Avg Closing Trade (90 D):	$40.82M
Avg Closing Volume:	80.21K

News

Jul 18, 2025 @ 5:00 AM Press Release: Sanofi completes acquisition of Blu... Source: Sanofi Press Release

Jul 18, 2025 @ 5:00 AM Communiqué de presse : Sanofi finalise lâ€â„... Source: Sanofi Press Release

Jul 17, 2025 @ 5:00 AM Press Release: Sanofi announces extension of Bluep... Source: Sanofi

Jul 17, 2025 @ 5:00 AM Communiqué de presse : Sanofi annonce la prolon... Source: Sanofi

Jul 14, 2025 @ 10:30 PM $HAREHOLDER ALERT: The M&A Class Action Firm Annou... Source: Juan Monteverde

Financials
	TTM	Q1 2025	Q4 2024
Basic EPS	$-2.48	$.01	$-.8
Diluted EPS	$-2.48	$.01	$-.8
Revenue	$562.12M	$149.41M	$146.37M
Gross Profit	$542.35M	$146.61M	$138.92M
Net Income / Loss	$-155.73M	$.5M	$-49.96M
Operating Income / Loss	$-174.31M	$-41.09M	$-41.2M
Cost of Revenue	$19.77M	$2.8M	$7.45M
Net Cash Flow	$10.24M	$19.79M	$14.1M
PE Ratio